BioCentury | May 28, 2015
Targets & Mechanisms

Joint attack

...phosphorylation ( yellow ) of the peripheral membrane protein EZR , leading to association of EZR...
...of the phosphatase with SDC4, liberating active monomeric phosphatase molecules. The active phosphatase then dephosphorylates EZR...
...That reduces fibroblast migration, invasion, and attachment to cartilage and consequent RA pathology. EZR - Ezrin...
BioCentury | Oct 8, 2007
Company News

Bradmer management update

...development and manufacturing at NeoPharm Inc. Resigned: Kerry Barnhart as president and CSO, CEO Alan Ezrin...
BioCentury | Aug 13, 2007
Company News

Bradmer management update

...Brohman to chief business officer, while remaining CFO; and Alan Ezrin to CEO from COO; Ezrin...
BioCentury | Feb 26, 2007
Company News

Cardiome management update

...Cardiovascular Promoted: Don McAfee to CSO from VP of research; he replaces acting CSO Alan Ezrin...
BioCentury | Feb 20, 2001
Company News

Nortran management update

...Nortran Pharmaceuticals Inc. (VSE:NRT; NTRDF), Vancouver, B.C. Business: Cardiovascular, Neurological, Pulmonary Hired: Alan Ezrin as CSO...
BioCentury | Jul 14, 1997
Emerging Company Profile

RedCell Canada Inc.

...Grand Montreal, Partech International, Sofinnova, Sequoia Capital, Technology Funding and European Medical Partners CEO: Alan Ezrin...
BioCentury | Jul 14, 1997
Emerging Company Profile

RedCell: Permanent bonds

...make it a more desirable target than RBCs, according to RedCell President and CEO Alan Ezrin...
...Late-stage clinical compounds with overly-short half-lives or excessive side effects also may be good targets, Ezrin...
...slow tapering of its long-circulating compounds will get patients past the critical point, avoiding rebound, Ezrin...
BioCentury | Jun 9, 1997
Company News

RedCell management update

...tranche of private placement, B15) RedCell Canada Inc., Montreal, Quebec Business: Drug delivery Promoted: Alan Ezrin...
Items per page:
1 - 8 of 8